RecruitingPhase 2NCT06302569
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
Studying Collecting duct carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Giuseppe Procopio
- Principal Investigator
- Giuseppe Procopio, MDFondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
- Intervention
- Pembrolizumab + Enfortumab Vedotin(drug)
- Enrollment
- 23 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (1)
- Fondazione Irccs Istituto Dei Tumori Di Milano, Milan, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06302569 on ClinicalTrials.govOther trials for Collecting duct carcinoma
Additional recruiting or active studies for the same condition.